Effect of Pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus

American Journal of Cardiology

Volumn 92, Issue 2, 2003, Pages 121-124

  Lee, Sung Joon ^b   Sacks, Frank M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0038306403     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(03)00524-1     Document Type: Article

References (19)

1. Fruchart J.C. Insulin-resistance and lipoprotein abnormalities. Diabete Metab. 17:1991;244-248.
2. Erkelens D.W. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol. 88:(suppl):2001;38J-42J.
3. Wang C.S., McConathy W.J., Kloer H.U., Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J Clin Invest. 75:1985;384-390.
4. Ginsberg H.N., Le N.A., Goldberg I.J., Gibson J.C., Rubinstein A., Wang-Iverson P., Norum R., Brown W.V. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest. 78:1986;1287-1295.
5. McConathy W.J., Gesquiere J.C., Bass H., Tartar A., Fruchart J.C., Wang C.S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res. 33:1992;995-1003.
6. Ebara T., Ramakrishnan R., Steiner G., Shachter N.S. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. J Clin Invest. 99:1997;2672-2681.
7. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 266:1991;18259-18267.
8. Chivot L., Mainard F., Bigot E., Bard J.M., Auget J.L., Madec Y., Fruchart J.C. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Atherosclerosis. 82:1990;205-211.
9. Alaupovic P., Mack W.J., Knight-Gibson C., Hodis H.N. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol. 17:1997;715-722.
10. Sacks F.M., Alaupovic P., Moye L.A., Cole T.G., Sussex B., Stampfer M.J., Pfeffer M.A., Braunwald E. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102:2000;1886-1892.
11. Luc G., Fievet C., Arveiler D., Evans A.E., Bard J.M., Cambien F., Fruchart J.C., Ducimetiere P. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde . J Lipid Res. 37:1996;508-517.
12. Gervaise N., Garrigue M.A., Lasfargues G., Lecomte P. Triglycerides, apo C3, and Lp B: C3 and cardiovascular risk in type II diabetes. Diabetologia. 43:2000;703-708.
13. Lee SJ, Campos H, Moye LA, Sacks FM. LDL particles containing apolipoprotein CIII are independent risk factors for coronary events in diabetic patients. Arterioscler Thromb Vasc Biol 2003;23:853-858.
14. Weisgraber K.H., Innerarity T.L., Harder K.J., Mahley R.W., Milne R.W., Marcel Y.L., Sparrow J.T. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem. 258:1983;12348-12354.
15. Sacks F.M., Alaupovic P., Moye L.A. Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. Am J Cardiol. 90:2002;165-167.
16. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 335:1996;1001-1009.
17. Lee S, Moye L, Campos H, Williams G, Sacks F. Hypertriglyceridemia but not diabetes status is associated with VLDL containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 2003;167:293-302.
18. Leonhardt W., Pietzsch J., Nitzsche S. Very-fast ultracentrifugation of human plasma lipoproteins influence of the centrifugal field on lipoprotein composition . Clin Chim Acta. 224:1994;21-32.
19. Pietzsch J., Subat S., Nitzsche S., Leonhardt W., Schentke K.U., Hanefeld M. Very fast ultracentrifugation of serum lipoproteins influence on lipoprotein separation and composition . Biochim Biophys Acta. 1254:1995;77-88.